Wells Fargo analyst Larry Biegelsen raised his price target for Baxter to $89 from $80 as he believes the company has a “robust near-term pipeline” that will produce a number of important launches in late 2019 through 2020 to help accelerate sales growth from 2020 to 2023. The analyst reiterates an Outperform rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.